{"id":195459,"date":"2026-01-09T06:19:37","date_gmt":"2026-01-09T06:19:37","guid":{"rendered":"https:\/\/legalvision.co.uk\/?p=195459"},"modified":"2026-02-13T00:51:46","modified_gmt":"2026-02-13T00:51:46","slug":"ai-drug-intellectual-property","status":"publish","type":"post","link":"https:\/\/legalvision.co.uk\/intellectual-property\/ai-drug-intellectual-property\/","title":{"rendered":"AI Drug Discovery: Protecting Your Intellectual Property"},"content":{"rendered":"\n

The pharmaceutical industry is experiencing dramatic changes as a result of the recent advances in AI technology. Artificial intelligence<\/a> is now capable of identifying potential drug candidates much more quickly, analysing vast datasets to predict molecular interactions, and optimising compound structures with precision. For UK small and medium-sized enterprises operating in this space, the competitive advantage lies not just in developing these AI-driven discoveries but in protecting them effectively.\u00a0This article covers how life sciences businesses can protect and commercialise IP created through AI-driven drug discovery.<\/p>\n\n\n\n

AI Algorithm Protection<\/h2>\n\n\n\n

The algorithms powering your drug discovery platform represent a significant investment and competitive advantage. In the UK, software and mathematical methods are generally not patentable on their own, but AI algorithms that produce a technical effect or solve a technical problem may qualify for patent protection. The key is demonstrating that your algorithm goes beyond mere data processing to achieve a concrete technical application in drug discovery.<\/p>\n\n\n\n

Copyright automatically protects<\/a> the source code of your AI system, but this offers limited commercial protection since it does not prevent others from developing algorithms that have similar functionality independently, provided the source code is different. If your goal is to protect your IP as comprehensively as possible, you could keep core algorithmic innovations as trade secrets, while pursuing patent protection for specific technical implementations that meet patentability criteria.<\/p>\n\n\n\n

Drug Discovery Patents<\/h2>\n\n\n\n

Drug candidates identified through AI can present issues for patent eligibility. Traditional pharmaceutical patents cover novel chemical compounds, their manufacturing processes, and therapeutic applications. However, when AI generates these discoveries, it can be difficult to ascertain who the \u2018inventor\u2019 is, and therefore, meet the degree of human contribution required for patent validity.<\/p>\n\n\n\n

\n

UK patent law requires human inventors, so your patent applications must clearly demonstrate the human creative contribution in the discovery process, even if AI conducted much of the analysis. Keep documentation of how researchers selected training data, interpreted the output from the AI, and made decisions that ultimately led to the final drug candidate.<\/p>\n<\/div>\n\n\n\n\n\n Continue reading this article below the form\n <\/i>\n<\/a>\n

\n
\n Need legal advice?\n
\n \n Call 0808 196 8584<\/a> for urgent assistance.\n
\n Otherwise, complete this form, and we will contact you within one business day.\n <\/span>\n <\/div>\n\n \n\n
\n